NVRO's fourth-quarter earnings surpass the Zacks Consensus Estimate, while worldwide revenues decline year over year. The ...

Nevro Corp (NYSE:NVRO) is set to release its Q4 2024 earnings on Mar 4, 2025. The consensus estimate for Q4 2024 revenue is ...

Nevro Corp. (NYSE:NVRO – Get Free Report) has earned a consensus rating of “Reduce” from the thirteen research firms that are ...

Reports Q4 revenue $105.5M, consensus $102.61M. Cash, cash equivalents and short-term investments totaled $292.5M as of December 31, 2024, an ...

Analysts at StockNews.com initiated coverage on shares of Nevro (NYSE:NVRO – Get Free Report) in a research note issued on ...

As previously announced on February 6, given the pending acquisition of Nevro (NVRO) by Globus Medical, Nevro is not issuing FY25 guidance, nor ...

REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic ...

REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Nevro Corp. (NVRO) on Tuesday reported a loss of $53.1 million in its fourth quarter. On a per-share basis, the Redwood City ...

Management uses certain non-GAAP financial measures, most specifically adjusted EBITDA, as a supplement to GAAP financial measures to further evaluate the Company's operating performance period ...

U.S. revenue in the fourth quarter of 2024 was $91.4 million, a decrease of 9.9% compared with $101.5 million in the prior year period. U.S. permanent implant procedures decreased by 7.0% compared ...